Antihyperglycemic effect of a chicken feet hydrolysate via the incretin system: DPP-IV-inhibitory activity and GLP-1 release stimulation. Issue 7 (21st June 2019)

• Record Type: Journal Article
• Authors: Casanova-Martí, Àngela; Bravo, Francisca Isabel; Serrano, Joan; Ardévol, Anna; Pinent, Montserrat; Muguerza, Begoña
• Is Part Of: Food & function. Volume 10:Issue 7(2019)
• Page Start: 4062
• Page End: 4070
• Publication Date: 2019-06-21
• Subjects: Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; Nutrition -- Periodicals; 664.07
• DOI: 10.1039/c9fo00695h
• Languages: English
• ISSNs: 2042-6496

Abstract

Abstract : The potential of hydrolysates of chicken feet proteins as natural DPP-IV inhibitors was investigated. After a screening, one hydrolysate was tested in vivo and showed antihyperglicemic effect. In addition, it stimulated GLP-1 in vitro and ex vivo . Abstract : Herein, the potential of hydrolysates of chicken feet proteins as natural dipeptidyl-peptidase IV (DPP-IV) inhibitors was investigated; moreover, three hydrolysates were selected due to their high DPP-IV inhibitory capacity (>80% inhibition), showing the IC50 values of around 300 μg estimated protein per mL; one of them (named p4H) was selected for the posterior analysis. In addition, its effect on glucose tolerance was investigated in two rat models (diet and age-induced) of glucose-intolerance and healthy animals; the amount of 300 mg estimated peptide per kg body weight improved the plasma glucose profile in both glucose-intolerance models. Moreover, it stimulated active GLP-1 release in the enteroendocrine STC-1 cells and rat ileum tissue. In conclusion, our results indicate that chicken feet proteins are a good source of bioactive peptides as DPP-IV inhibitors. Moreover, our results highlight the potential of the selected hydrolysate p4H in the management of type 2 diabetes due to its dual function of inhibition of the DPP-IV activity and induction of the GLP-1 release.